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Different approaches have been used to
mitigate the morbidity and mortality as-
sociated with cytomegalovirus (CMV) in-
fection after solid organ transplantation
[1]. Agents such as CMV hyperimmune
globulins, acyclovir, valaciclovir, ganciclo-
vir, and valganciclovir have been used
preemptively or prophylactically in nu-
merous clinical studies. However, a ma-
jority of these studies were neither de-
signed nor powered adequately to answer
the most important questions they were
supposed to have addressed. In fact, a few
large prophylactic studies [2–4] have
helped promote prophylaxis, but there is
still a significant debate between support-
ers of the preemptive and of the prophy-
lactic methods [5–7], resulting in some-
what complex guidelines for the
management of CMV infection [8, 9]. In
addition, over the years, it has been rec-
ognized that, aside from direct effects (i.e.,
morbidity directly attributable to CMV in-
fection), CMV as an immunoregulatory
virus is also responsible for indirect effects
(i.e., acute and perhaps chronic allograft
rejection and secondary fungal and bac-
terial infections) [10]. Finally, it has been
realized that prophylaxis against CMV dis-
ease modifies the time course of the viral
infection, causing late-onset disease,
which typically occurs after prophylaxis
discontinuation [3, 11]. This has led to
the definition of new end points and to
an increase in the duration of follow-up
as necessary parts of any study evaluating
the management of CMV infection after
transplantation. In view of the paucity of
evidence and the lack of consensus re-
garding the optimal method for prevent-
ing CMV infection, it was tempting to try
to make the best use of data by meta-
analysis of existing studies.
In this issue of Clinical Infectious Dis-
eases, Small et al. [12] publish the fourth
meta-analysis of antiviral therapies for
preemptive or prophylactic approaches to
CMV infection in solid organ transplant
recipients [13–15]. Unlike the studies by
Hodson et al. [14] and Strippoli et al. [15],
which are meta-analysis studies compar-
ing universal prophylaxis and preemptive
therapy with placebo, respectively, Small
et al. [12], like Kalil et al. [13], conducted
a meta-analysis of randomized, controlled
studies using either the preemptive or the
prophylactic approach and calculated the
relative risk for CMV disease, mortality,
organ rejection, graft loss, and opportun-
istic infection for each approach, com-
pared with placebo. In addition, Small and
colleagues statistically compared the rela-
tive risk conferred by each antiviral ap-
proach. Small and colleagues have used
somewhat different inclusion criteria re-
garding quality of randomization and
blinding leading to the analysis of a set of
studies that is larger than that of previous
meta-analyses [13–15]. Perhaps more im-
portantly, Small and colleagues used a re-
stricted definition of active anti-CMV
therapy based on the use of ganciclovir or
valganciclovir, compared with any other
approach (including acyclovir based-reg-
imens) that was deemed suboptimal
enough to be considered a control. In so
doing, it focused on a somewhat more
homogeneous group of studies regarding
the active arm (ganciclovir or valganciclo-
vir), but it included as controls quite in-
homogeneous groups of patients who may
have received partly effective anti-CMV
drugs, which probably accounted in part
for the extraordinary range of CMV dis-
ease incidence in the control groups (5%–
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90%). Of note is that this methodology
led to the exclusion of the largest pro-
phylaxis study of kidney transplant recip-
ients, in which the active arm received a
large dose of valaciclovir, an effective pro-
phylactic regimen [3]. Indeed, it is inter-
esting to compare the results of the various
meta-analyses that have been performed
to date and to see what they reveal (or do
not reveal) in terms of CMV infection pre-
vention efficacy.
Regarding the incidence of CMV dis-
ease, the present analysis suggests a statis-
tically nonsignificant trend of greater risk
reduction with preemptive therapy, com-
pared with universal prophylaxis. By com-
parison, Kalil et al. [13] found a higher
risk reduction with universal prophylaxis,
and these discordant trends may be ex-
plained by the differences in the definition
of the control group, as noted above. In
addition, a pitfall exists in the analysis of
the preemptive approach that pertains to
the time of randomization. In some stud-
ies [16], patients were monitored for vi-
remia and were randomized at the time
they tested positive for viremia to receive
either preemptive therapy or placebo. In
this strategy, patients presenting with con-
current viremia and CMV disease are not
eligible for enrollment, although, arguably,
they should be counted as failures of the
preemptive approach. In fact, among pa-
tients considered for enrollment in pre-
emptive studies included in the meta-anal-
ysis by Strippoli et al. [15], 0%–32% were
excluded because CMV disease developed
before (or concurrently with) CMV vire-
mia, possibly leading to an overestimate
of the efficacy of the preemptive approach
at preventing CMV morbidity.
Indeed, the analysis by Small et al. [12]
would be a lot more informative if the
study data allowed for separate analysis of
the incidence of early-onset (!3 months)
and late-onset (13 months) CMV disease
and if the analysis had been performed by
stratifying patients in high-risk (donor
[+]/recipient []) and intermediate-risk
(donor [+]/recipient [+] and donor []/
recipient [+]) groups. From several large-
scale prophylactic studies [2, 3], we know
that universal prophylaxis, especially use
of state-of-the-art valganciclovir [4], is
close to 100% effective at suppressing vi-
remia and preventing CMV disease, even
in high-risk patients, for the period of pro-
phylaxis. During that period, the preemp-
tive approach will have at least a failure
rate corresponding to the concurrent pre-
sentation of viremia and disease.
After discontinuation of prophylaxis,
some patients experience late-onset CMV
disease, but at a reduced rate and severity,
compared with what they would have ex-
perienced earlier in the absence of pro-
phylaxis [3, 4]. It has been hypothesized
that the preemptive approach, by allowing
some early CMV replication and immune
stimulation, may be associated with a re-
duced rate of late-onset CMV disease,
compared with prophylaxis [17]. How-
ever, there are very few data from ran-
domized studies to support this view. At
our institution, in a noncomparative study
of the preemptive approach, we reported
that donor (+)/recipient () recipients
were at a high risk of experiencing a pro-
tracted course of CMV infection lasting
up to several months, a result that is in-
consistent with the hypothesis that some
early viral replication in the frame of the
preemptive strategy is sufficient to gen-
erate protective immune responses [18].
Overall, although this new meta-analysis
reveals a similar efficacy of the prophy-
lactic and preemptive approach (reducing
CMV disease incidence by approximately
two-thirds), it fails to reveal important in-
formation regarding the efficacy of pro-
phylaxis during and after drug adminis-
tration, as shown by large prophylactic
studies [2–4].
Regarding acute rejection, one is struck
again by the extraordinary range of acute
rejection incidence among trials (3%–
74%). Besides inclusion of different organ
transplant categories and different defi-
nitions of acute rejection, this high range
may be a result of the large time period
during which these studies were con-
ducted, a period during which there has
been major progress in the immunosup-
pressive regimens. It is an irony that this
meta-analysis excluded the Lowance study
[3], which demonstrated that CMV pro-
phylaxis reduces the rate of acute rejection
in high-risk (donor [+]/recipient []) pa-
tients, and that, interestingly, the post-pro-
phylaxis recrudescence of late-onset CMV
disease does not translate into an increase
in acute rejection. Again, we wonder
whether the present analysis failed to de-
tect a significant risk reduction for acute
rejection, in contrast to the findings of
Kalil et al. [13], because in some studies,
quite active prophylaxis was considered to
be a control.
As acknowledged by Small et al. [12],
the failure of detecting effects regarding
other end points, such as mortality, graft
loss, and opportunistic infection, may re-
flect the lack of data rather than the lack
of effect of either approach. Indeed, other
meta-analyses have indicated that univer-
sal prophylaxis is associated with a de-
crease in the incidence of viral, bacterial,
and fungal infections, as well as a decrease
in the number of patient deaths [13, 14].
In fact, the present paper is a new and
useful attempt at making the best use of
data generated over the past 15 years. Con-
sidering the small number of eligible stud-
ies, especially studies of the preemptive ap-
proach, and the relatively small size of the
majority of those studies (see tables 1 and
2 of Small et al. [12]), one can only agree
with the authors’ conclusion that, ulti-
mately, “additional trials that directly
compare the 2 prevention strategies are
warranted and needed before the CMV
prevention debate can be resolved” [12, p.
878]. Such clinical trials should monitor
for CMV infection and disease at least for
1 year after transplantation and analyze
data by stratifying patients according to
their CMV donor/recipient serostatus and
analyzing late CMV disease separately.
More importantly, such trials should also
include data regarding chronic allograft
dysfunction, because it is suspected that
CMV-related events and their manage-
ment in the early months following trans-
EDITORIAL COMMENTARY • CID 2006:43 (1 October) • 883
plantation may affect subsequent chronic
allograft injury [19].
Where do we go from here? For the
most part, the transplant infectious disease
community has been working in a rela-
tively small-scale, single-center, single
transplant–program manner, and the time
has come to organize larger prospective
transplant cohorts to facilitate the analysis
of sufficient numbers of transplant pa-
tients. The organization of a large, ran-
domized, controlled trial, such as the one
proposed by Small et al. [12], would cer-
tainly reveal to us the relative merits of
the preemptive approach versus the pro-
phylactic approach, particularly regarding
late-onset CMV disease, chronic allograft
injury, and cost effectiveness. After taking
into account the different incidences of
CMV disease in various organ transplant
populations and serostatus patterns, the
answers may be found to vary accordingly.
Similar multicenter studies should also ad-
dress questions regarding optimal dose
and duration of universal prophylaxis with
modern efficacious agents, such as val-
ganciclovir. It is likely that a few well-or-
ganized, randomized, controlled trials will
produce much more evidence than well-
conducted meta-analyses of many small,
nonstandardized studies.
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